Infusion Revenue Intelligence
Protect high-value treatments with intelligent authorization workflows, infusion coding validation, claims management, and reimbursement visibility.
Eight Streams. One Connected Revenue Cycle.
Infusion Revenue Intelligence
Sample
Illustrative sample. Not a customer result.
Photographs show the care setting. RSAI does not examine patients, prepare medication, read specimens, or perform surgery.
Infusion center revenue cycle management ties a clinical calendar to a drug invoice. The same chair can deliver infliximab one hour and a different biologic the next. Each drug has its own unit, authorization, and administration family.
The revenue risk is concentrated. One denied drug line can be worth more than a week of evaluation-and-management visits.
Buy-and-bill reimbursement depends on the payer’s allowed amount for the HCPCS code and on the units billed. The unit is defined by the code. J1745 is 10 mg of infliximab, excluding biosimilars. J3380 is 1 mg of intravenous vedolizumab. J2350 is 1 mg of ocrelizumab. Confirm the current CMS quarterly file before using any of those units.
RSAI does not calculate medication profitability and does not tell a center which drug to buy.
Infusion prior authorization is often a window, not a permanent yes. A dose scheduled after the end date, or a dose that exceeds the authorized amount, is a preventable denial.
Staff still read the payer’s letter. Automation tracks the dates. It does not negotiate the clinical policy.
Units are dose divided by the code’s billing unit, under that payer’s rounding rules. A vial remainder is not automatically a billable unit.
Hydration (96360, 96361), therapeutic infusion (96365, 96366), sequential infusion (96367), concurrent infusion (96368), and chemotherapy administration (96413, 96415) answer different questions. Chemotherapy administration codes are not the default for every infused drug.
Medicare has discarded-drug reporting for separately payable single-use drugs, including the JW and JZ modifiers. Whether a remainder is payable depends on the drug, the package, and the payer.
Confirm the current CMS discarded-drug policy. RSAI does not decide wastage for the center. The documentation has to come from the administration record.
Infusion claim denials often cite authorization, medical necessity, units, or a bundled administration. An underpayment is a paid line that does not match the expected allowed amount. Comparing those figures is a review step. The numbers on this page are illustrative.
Payment forecasting concepts, such as a typical payer lag, are planning aids. RSAI does not claim an operational forecast that predicts a deposit date or an amount.
The platform helps the center’s own team move eligibility, authorization tracking, coding assistance, claim edits, and status checks off a manual list. People still confirm the drug, the dose, and the appeal.
RSAI is not an outsourced billing company and it does not staff the infusion chair.
An outsourced billing service takes the account and usually prices work as a percentage of collections. That percentage falls on drug collections as well as service collections.
RSAI is software the center’s team runs: a platform fee plus credits. The center keeps the payer contracts, the clinical record, and the decision to appeal.
Workflow
Six stages from insurance verification to payment tracking. The clinical team administers the infusion. RSAI does not perform treatment.
Coding intelligence
Representative infusion CPT and HCPCS examples for coding review. Short categories only. CPT is a registered trademark of the American Medical Association. Confirm descriptors, units, modifiers, and payer rules for the date of service.
Swipe sideways to read every column.
| Code | Category | What to confirm |
|---|---|---|
| 96360 | Initial intravenous hydration | Not a therapeutic infusion. Hydration has its own time rules. |
| 96361 | Additional hour of intravenous hydration | Requires the additional time. It is not an automatic add-on to every bag. |
| 96365 | Initial therapeutic intravenous infusion | The usual initial code for many non-chemotherapy drug infusions. |
| 96366 | Additional hour of therapeutic infusion | Depends on documented time past the initial hour. |
| 96367 | Sequential therapeutic intravenous infusion | A different drug, after the first infusion, up to one hour. Not a concurrent infusion. |
| 96368 | Concurrent intravenous infusion | A different drug running at the same time. Payers scrutinize this. |
| 96413 | Initial chemotherapy administration infusion | Only when the drug qualifies. Not a synonym for any biologic. |
| 96415 | Additional hour of chemotherapy administration | Same qualification as the initial chemotherapy code, plus time. |
Swipe sideways to read every column.
| Code | Category | What to confirm |
|---|---|---|
| J1745 | Infliximab, biosimilars excluded, per 10 mg | Confirm the CMS HCPCS quarterly file. Biosimilars are reported with other codes. |
| J3380 | Vedolizumab, intravenous, per 1 mg | Billing unit is 1 mg. Confirm the current file before calculating units. |
| J2350 | Ocrelizumab, per 1 mg | Billing unit is 1 mg. Indication and payer policy are separate from the code existing. |
These codes do not all apply to the same visit. Chemotherapy administration is not implied for every infused drug. Modifiers, including discarded-drug modifiers, apply only when the payer’s rule for that drug is met. Nothing here is a billing instruction for a specific patient.
HCPCS units are paraphrased from the CMS quarterly file. Confirm the current CMS HCPCS update. Discarded-drug reporting, when it applies, is described by CMS discarded-drug policy. Global surgery rules live on the Medicare physician fee schedule. CPT® is a registered trademark of the American Medical Association. RSAI does not reproduce AMA long descriptors.
Streams
The streams below are the ones most used for this specialty. They are part of the same eight. Stream Orchestrator is the coordination layer. It is not a ninth stream.
Tracks medication authorization windows so a later dose is not given on an expired approval.
Assists review of administration families and drug units. A coder confirms the claim.
Supports claim validation and denial work after the infusion is coded.
Patient responsibility on an infusion remittance still has to be explained and collected.
Shows whether the claim is pending, paid, or reduced, without a manual portal check for every line.
All eight streams: StreamDesk, StreamVerify, StreamAuth, StreamCode, StreamClaim, StreamBill, StreamCall, StreamStatus. See the stream suite.
Questions
No. Nurses and physicians administer treatment. RSAI supports the revenue cycle around that treatment.
No. Every figure on the infusion dashboard is an illustrative sample for layout. It is not a customer result.
No. 96413 and 96415 require the drug to qualify. Therapeutic infusion codes are a different family.
No. Payment timing concepts are discussed as planning ideas. Medication profitability is not an RSAI product claim.
Bring the authorization calendar, the coding review, and the remittance onto one platform your team still controls.